Navigation Links
MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
Date:6/14/2010

WOONSOCKET, R.I., June 14 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

In an earlier Phase IIa study, MCT-125 was tested on 138 patients suffering from PMSF.  MCT-125 was shown to be effective within 4 weeks of administration, was active across all multiple sclerosis (MS) disease severity assessment scales, and on patients regardless of MS disease sub-type (primary progressive, secondary progressive and relapsing-remitting).

MCT-125 is a fixed dose, orally delivered, combination therapeutic acting on noradrenergic neurons and tyrosine hydroxylase to block the reuptake of noradrenaline with little or no direct action on serotoninergic neurons.  The synthesis of noradrenaline in noradrenergic neurons is tightly regulated by tyrosine hydroxylase acting as the key rate-limiting step.  MCT-125 is thought to lead to the greater availability of noradrenaline in the central nervous system resulting in a decrease in fatigue levels.

Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the myelin sheath insulating neurons in the brain and spinal cord.  Approximately 350,000 individuals have been diagnosed with MS in the United States, and more than two million persons worldwide are afflicted with this disease.  An estimated 10,000 new MS cases are diagnosed in the USA annually.  

PMSF comes on suddenly, and is overwhelming in proportion to any activity undertaken.  PMSF can severely affect an MS patient's quality of life, ability to function, and ability to feel they have control over their illness.  MS patients with PMSF experience an overwhelming tiredness, lack of energy, and a feeling of exhaustion.  The causes of fatigue in MS are thought be partly the result of the disease process itself, and partly the result of other factors (secondary fatigue) that affect a person with MS more significantly than people without the disease.  PMSF affects over 70% of persons with MS.  Pharmacological treatment options for PMSF are limited, and no drug has been specifically approved by the U.S. Food and Drug Administration for the treatment of PMSF.

About Clinical Development & Support Services, Ltd.

Clinical Development & Support Services, Ltd. provides a wide range of clinical development services to the pharmaceutical, biotechnology and medical device industries.  CDSS is a clinical research organization specializing in the management of clinical trials including the provision of study site coordination/research nursing services.  CDSS manages all phases of clinical development from the first administration of drugs in humans through to post-marketing studies.  For more information about CDSS, please visit http://www.cdssltd.com.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs.  MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2009, and all our quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
3. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
4. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
5. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
6. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
7. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
8. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
9. Accuray Hires General Manager for Japan
10. Ascension Orthopedics Hires Key Senior Executives
11. Accuray Hires General Manager for the EIMEA Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has ... for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 ... and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per ... in adults and children 6 years of age and older. ... approximately $16 million.   ...
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/17/2017)... partnership with CitiHope , Panexus Haiti ... Jack Brewer Foundation (JBF Worldwide) has sent a ... medicine to Innovating Health International (IHI) in ... to treating chronic diseases and addressing women,s health issues in developing ... and providing these medicines to the organization ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow ... Tri-Conference February 20 – 22 in San Francisco. As part of the Tri-Conference ... molecular pathology workflow solution, as well as its new precision medicine platform, “Crosswalk ...
(Date:2/17/2017)... ... ... Top neuroendocrine cancer doctors, nurses and specialists from around the world will ... in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive director of ... hosting over 60 faculty members and addressing unmet needs of the NET community. ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... financial planning assistance to families and business owners in the greater Fort Lauderdale ... Families organization. , For more than 30 years, LifeNet 4 Families has ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
Breaking Medicine News(10 mins):